feedback welcome

Clomipramine-bupropion

From Psychiatrynet

(Difference between revisions)
Jump to:navigation, search
[draft revision][draft revision]
Line 6: Line 6:
* '''Day 1-3:''' reduce dosage of clomipramine to 50 mg/day.
* '''Day 1-3:''' reduce dosage of clomipramine to 50 mg/day.
* '''Day 4-7:''' reduce dosage of clomipramine to 25 mg/day.
* '''Day 4-7:''' reduce dosage of clomipramine to 25 mg/day.
 +
* '''Day 8:''' stop administration of clomipramine.
| start =  
| start =  
* '''Day 1:''' simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of clomipramine according to the scheme above.
* '''Day 1:''' simultaneously start administration of bupropion in a dosage of 150 mg/day and continue administration of clomipramine according to the scheme above.
-
* '''Day 8:''' stop administration of clomipramine and continue administration of bupropion only in a dosage of 300 mg/day.
+
* '''Day 8:''' continue administration of bupropion in a dosage of 300 mg/day.
| info =  
| info =  
* Bupropion is a strong inhibitor of CYP2D6, which metabolizes clomipramine.
* Bupropion is a strong inhibitor of CYP2D6, which metabolizes clomipramine.
  }}
  }}

Revision as of 11:40, 24 June 2009

Clomipramine
Type Antidepressant
Group TCA
links
ATC-code N06AA04
Medscape Clomipramine
PubChem 2801
PubMed Clomipramine
Kompas (Dutch) Clomipramine
Wikipedia Clomipramine
Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion

Switch medication from clomipramine to bupropion.

Nietinrijdenbord.png Stop clomipramine
Eenrichtingbord.png Start bupropion
Infobord.png More information
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
Navigation
About